Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Hedge funds track equities to record levels in Q1 2013; HFRI Fund Weighted Composite Index +1.2% in March (+3.9% Q1)

Saturday, April 06, 2013
Opalesque Industry Update: Hedge funds extended gains in March to conclude 1Q13 at record levels, tracking U.S. equity performance, which also advanced to close the quarter at new highs. The HFRI Fund Weighted Composite Index gained +1.2 percent in March bringing the 1Q13 gain to +3.9 percent, with top contributions from Fixed Income-based Relative Value Arbitrage and Equity Hedge and strategies, as reported today by HFR, the established global leader in the indexation, analysis and research of the global hedge fund industry.

The HFRI Fund Weighted Composite Index closed 1Q13 with a net asset value (NAV) of 11,482, surpassing the previous peak set in April 2011, concluding a 20-month drawdown in 1Q and creating a new performance high watermark for the industry. An investment of $1,000 in the hedge fund industry at the start of 1990, as represented by the HFRI, would have grown to $11,482 as of the end of 1Q13, an 11.5x increase. A similar investment in the S&P 500 would have grown by approximately 7.3 times.

March gains were led by Fixed Income-based Relative Value Arbitrage strategies, with the HFRI Relative Value Arbitrage Index gaining +1.5 percent in the month and +3.8 percent for 1Q13. RV gains were driven by credit multi-strategy and yield alternative exposures (including MLPs), with the HFRI RV: Multi-Strategy Index gaining +2.9 percent in March and +5.2 percent for the quarter, while the HFRX MLP Index gained +15.4 percent for 1Q13.

Equity Hedge led strategy gains for 1Q13, as the HFRI Equity Hedge Index gained +1.5 percent in March and +5.3 percent for the quarter; Fundamental Value strategies advanced +7.2 percent in 1Q while HFRI EH: Technology/Healthcare Index gained +6.3 percent for the quarter.

As a direct result of the dynamic and robust environment for corporate transactions and increased shareholder accountability pressures, Event Driven hedge funds also made positive contributions to industry performance, with the HFRI Event Driven Index gaining +1.0 percent for March and +3.8 percent for 1Q13. Hedge Funds focused on Special Situations advanced +4.7 percent for the quarter, while Activist managers gained +8.6 percent in 1Q13.

Macro funds also posted gains in the first quarter, but these were tempered by commodity declines, currency reversals and falling equity volatility. The HFRI Macro Index gained +0.5 percent in March and +1.4 percent for 1Q13, with Active Trading and Currency-focused strategies gaining +3.2 and +2.0 percent, respectively, for the quarter. The HFRI Macro: Systematic Diversified CTA Index gained +1.2 percent for 1Q13, while Commodity focused strategies declined by -1.0 percent.

The HFRI Fund of Hedge Funds Index gained +1.0 percent in March, while the HFRI Emerging Markets Index declined by -1.0 percent for the month, paring its 1Q13 gain to +2.4 percent.

“Despite certain differences, 2013 has started in a very similar manner to 2012, with a risk-on trading environment contributing to strong performance from equities and more balanced gains from hedge funds as Macro risks remained pronounced,” said Kenneth J. Heinz, President of HFR. “Extensive stimulus and quantitative easing have comprised a base of support for U.S. & Japanese equities in recent months, but the risks of competitive currency devaluations, extraction of QE stimulus and evidence of labor market weakness have grown as well, prompting many managers to adopt conservative positioning by reducing net exposure to the equity market rally. Through this environment, hedge funds are likely to continue producing balanced gains in coming quarters, independent of the prevailing risk regime and trading conditions.”

HFR

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for